指南与共识胰腺与胆道疾病消化道肿瘤与早癌

家族性胰腺癌高风险人群管理:CAPS联盟更新推荐

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
指南 / 共识 · Gut · 2019-10-31

国际胰腺癌筛查联盟(CAPS)于2018年召开会议,采用改良Delphi法更新高风险人群胰腺癌监测共识。共识达成55条声明,建议对特定高风险个体进行监测以发现高级别前驱病变和T1N0M0胰腺癌,推荐内镜超声和MRI/MRCP作为监测手段,但应在有经验的多学科中心研究背景下进行。

要点

  • 家族性风险者监测不早于50岁或比最年轻患病亲属早10年。
  • 生殖系ATM突变且有一名一级亲属患病者可考虑监测。
  • 首选内镜超声和MRI/MRCP,无异常病变时推荐每年监测。

核心结论

  • 建议对特定高风险个体进行胰腺监测以发现早期胰腺癌和高级别前驱病变。
  • 监测应在有适当专长的中心由多学科团队在研究背景下进行。

研究设计与样本

  • 国际胰腺癌筛查联盟(CAPS)于2018年召开会议更新共识推荐。
  • 采用改良Delphi法,由多学科专家组对共识声明进行投票。
  • 共识定义为≥75%同意或不同意。

主要发现

  • 共达成55条共识声明。
  • 监测主要目标为识别高级别不典型增生前驱病变和T1N0M0胰腺癌。
  • 对家族性风险者,监测应不早于50岁或比最年轻患病亲属早10年,但专家在50岁还是55岁开始上存在分歧。
  • 携带生殖系ATM突变且有一名一级亲属患病者现在被认为符合监测条件。
  • 首选监测手段为内镜超声和MRI/MRCP,但如何交替使用未达成共识;无异常病变时推荐每年监测。

关键数值与推荐

  • 共识达成阈值:≥75%同意或不同意。
  • 家族性风险者监测起始年龄:不早于50岁或比最年轻患病亲属早10年。
  • 生殖系ATM突变且有一名一级亲属患病者符合监测条件。
  • 首选监测手段:内镜超声和MRI/MRCP。
  • 无异常病变时推荐每年监测。

临床怎么用

  • 对符合条件的高风险个体应转诊至有经验的多学科中心进行研究性胰腺监测。
  • 监测方案可选用内镜超声或MRI/MRCP,无异常病变时每年复查。
  • 需向患者说明监测的获益、风险和成本尚需进一步评估。

局限性

  • 专家在监测起始年龄(50岁 vs 55岁)上存在分歧。
  • 未就内镜超声与MRI/MRCP如何交替使用达成共识。
  • 对遗传性胰腺炎是否及如何监测存在分歧。
  • 对不确定病变的管理存在分歧。
  • 支持推荐的证据有限,监测的获益、风险和成本需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). METHODS: A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed. RESULTS: Consensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions. CONCLUSIONS: Pancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2019. PMID: 31672839. doi:10.1136/gutjnl-2019-319352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。